ARDEA BIOSCIENCES (RDEA) rated Mkt Outperform with price target $35 by JMP Securities
JMP Securities rated Mkt Outperform ARDEA BIOSCIENCES (NASDAQ: RDEA) on 04/01/2010. Previously JMP Securities rated Mkt Outperform ARDEA BIOSCIENCES (NASDAQ: RDEA) on
03/13/2009., when the stock price was $11.60. Since then, ARDEA BIOSCIENCES has gained 175.52% as of 06/19/2012's recent price of $31.96. If you would have followed the previous JMP Securities's recommendation on RDEA, you would have gained 175.51% of your investment in 1194 days.
Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.
MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports.
JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.